

Celontin® (methsuximide) - First-time generic

- On May 15, 2023, <u>ANI Pharmaceuticals launched</u> an <u>AB-rated</u> generic version of Pfizer's <u>Celontin</u> (methsuximide) capsules.
 - ANI's generic Celontin was granted 180-days of competitive generic therapy exclusivity.
- Celontin is approved for the control of absence (petit mal) seizures that are refractory to other drugs.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.